Evidence map›Paper›PMID 40634807›Full record

ArticleAnnals of surgical oncology2025

Circulating Tumor DNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion.

Annie Liu, Ellery H Reason, Brittany G Sullivan, Benjamin Wildman-Tobriner, John H Strickler, S David Hsu, Susanna S Hill, Julie K M Thacker, Christopher R Mantyh, Billy Lan and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Annie LiuDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Ellery H ReasonDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Brittany G SullivanDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Benjamin Wildman-TobrinerDepartment of Radiology, Duke University Medical Center, Durham, NC, USA.
John H StricklerDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
S David HsuDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
Susanna S HillDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Julie K M ThackerDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Christopher R MantyhDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Billy LanDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Daniel NussbaumDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Sabino ZaniDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Peter J AllenDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Hope UronisDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
Michael E LidskyDepartment of Surgery, Duke University Medical Center, Durham, NC, USA. Michael.lidsky@duke.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatic arterial infusion (HAI) chemotherapy is an expanding treatment for patients with unresectable colorectal liver metastases (uCRLM). This study examined circulating tumor DNA (ctDNA) as a novel biomarker to prognosticate oncologic outcomes after HAI.

methodsThe study examined HAI outcomes for patients with uCRLM at Duke University from February 2022-December 2024. Signatera was used to determine circulating tumor DNA (ctDNA) quantity as mean tumor molecules per mL (MTM/mL). Survival outcomes were calculated from the date of HAI initiation and compared using Kaplan-Meier and Cox proportional hazards methods.

resultsIn this study, 37 patients had ctDNA collected with 20 months of median follow-up time.. The patients with pre-HAI ctDNA ≤ 100 MTM/mL had a significantly better overall survival (OS) (hazard ratio [HR] of 5.5 (95% confidence interval [CI] 1.3-22.7; p = 0.05). After 3 months of HAI, the patients whose ctDNA decreased by less than 75% had significantly worse progression-free survival (PFS) (< 75% vs 75-99% vs 100% decrease; median PFS, 3 vs 10 vs 11 months; p < 0.01, log rank test) and OS (< 75% vs 75-99% vs 100% change; median, 10 months vs not reached [NR] vs NR; p = 0.01, log rank test). Although the patients with initial carcinoembryonic antigen (CEA) ≤ 10 ng/mL had significantly better OS than those with a CEA > 10 ng/mL (HR 2.5; 95% CI 1-6; p = 0.04), the magnitude of CEA change after 3 months of HAI was not associated with OS or PFS.

conclusionsPreoperative ctDNA and ctDNA dynamics were associated with oncologic outcomes for patients who had uCRLM treated with HAI. These hypothesis-generating findings require validation before quantitative ctDNA is incorporated into patient selection algorithms and ctDNA dynamics are used to guide HAI therapy for uCLRM.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCirculating Tumor DNAColorectal NeoplasmsLiver NeoplasmsAdultAgedFemaleFollow-Up StudiesHepatic ArteryHumansInfusions, Intra-ArterialMaleMiddle AgedPrognosisSurvival RateBiomarkers, TumorCirculating Tumor DNA

Identifiers

PMID40634807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.